National Psoriasis Found. Consensus Defines On-Treatment Remission in Plaque Psoriasis as 0% BSA and MD global=0 for at

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
National Psoriasis Found. Consensus Defines On-Treatment Remission in Plaque Psoriasis as 0% BSA and MD global=0 for at least 6 months while on treatment. For both clinical practice and clinical trials. https://t.co/QJg0ZIQ5Mv https://t.co/0FnbFcpXQB
Links
https://buff.ly/u26mBDR

Survey shows only 1% of men are concerned about bone density; but 2 million men have osteoporosis, and 16 million men ha

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Survey shows only 1% of men are concerned about bone density; but 2 million men have osteoporosis, and 16 million men have osteopenia. https://t.co/DA4vSmj0vd? https://t.co/V4OChN022V
Links
Breaking the silence about men breaking bones https://buff.ly/KDefwtM

Rheumatology RoundUp: EULAR 2025

Increasing costs of biologics. X-sectional study of 76 781 psoriasis pts on biologics (TNFi, IL12/23, IL-17i, IL-23i)

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Increasing costs of biologics. X-sectional study of 76 781 psoriasis pts on biologics (TNFi, IL12/23, IL-17i, IL-23i) saw annual treatment cost increase from $21 236 in 2007 to $47 125 in 2021. AVG cost could have been 44% lower if lowest-cost Rx in same class was used https://t.co/IOaK75zsgg

By March 2025, the FDA has approved 71 biosimilars (15 interchangeable). The US & EU biosimilars markets spent $22.5

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
By March 2025, the FDA has approved 71 biosimilars (15 interchangeable). The US & EU biosimilars markets spent $22.58 billion in 2024 & is projected to increase by 25% to $171.79 billion by 2033 https://t.co/fsqGTzWuhC https://t.co/ZLYSIwRqI4
Links
Biosimilars Redefining Therapeutic Access: US & EU Markets on the Brink of $171… https://buff.ly/daCiHTh

Glucocorticoid Tapering in SLE

25 June 2025
Imaging in Axial Spondyloarthritis
The diagnosis of axial spondyloarthritis (axSpA) is clinical, however, there are still unmet needs, particularly in the diagnosis of early disease and evaluation of disease activity and progression. As imaging technology continues to evolve, its role in axSpA management is expected to expand, offering more precise, individualized care. Here are two studies presented at EULAR 2025.

New IL-17 Inhibition New Molecular Constructs

EULAR 2025 – RA Panel Discussion Leading experts in rheumatology dive into the latest advances, treatment strategies

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
EULAR 2025 – RA Panel Discussion Leading experts in rheumatology dive into the latest advances, treatment strategies, and emerging research in rheumatoid arthritis. Don’t miss this in-depth panel as they unpack key findings from EULAR 2025 and discuss what’s next for RA care. https://t.co/hoxz0zWieN
Subscribe to
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×